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The maintenance of intestinal homeostasis is 
complex, involving interactions between the 
intestinal microfl  ora, the epithelium, and the 
host immune system. A breakdown in the reg-
ulatory mechanisms that control homeostasis is 
thought to precipitate the dysregulated intesti-
nal infl   ammation that characterizes human 
  infl  ammatory bowel disease (IBD), including 
Crohn’s disease (CD) (1, 2). Although the 
  aetiopathogenesis of CD is not yet completely 
understood, it is widely held that chronic intes-
tinal infl  ammation is driven by the proinfl  am-
matory cytokine IL-12, which promotes the 
development of pathogenic Th1 CD4+ eff  ec-
tor cells (3, 4). This hypothesis was supported 
by results from several animal models of intes-
tinal infl  ammation in which disease develop-
ment could be blocked by treatment with 
monoclonal antibodies directed against the IL-
12p40 subunit (5, 6) or by using other strate-
gies to inhibit Th1 responses (7, 8). More 
recently, encouraging results were reported 
from initial clinical trials administering anti–IL-
12p40 monoclonal antibodies to human CD 
patients (9).
IL-12 is a heterodimeric type I cytokine 
comprising the IL-12p40 subunit together with 
the IL-12p35 subunit. The recent discovery 
that the IL-12p40 subunit can also combine 
with a specifi  c IL-23p19 subunit to form the 
closely related cytokine IL-23 (10) has led to a 
reappraisal of the roles of IL-12 and IL-23 in a 
variety of infl  ammatory disorders. Subsequent 
studies have clearly demonstrated that IL-23 is 
essential for driving several pathological reac-
tions, including the autoimmune pathologies 
present in experimental autoimmune encepha-
lomyelitis and collagen-induced arthritis (11–13). 
Like IL-12, IL-23 is primarily secreted by acti-
vated DCs, monocytes and macrophages, and 
transgenic mice constitutively overexpressing 
IL-23p19 develop fatal multiorgan infl  amma-
tion (14). The proinfl  ammatory activities of 
IL-23 have been partly ascribed to its ability to 
support the development of a novel subset of 
CD4+ infl  ammatory T cells known as Th17 
cells (15–17). Th17 cells are characterized by 
their production of IL-17 (IL-17A), IL-6, and 
TNF-α and have been associated with the 
  induction of autoimmune tissue infl  ammation 
(12, 18). Although the precise mechanism by 
which IL-23 promotes Th17 responses in vivo 
is still not completely understood, recent stud-
ies have shown that Th17 cell lineage commit-
ment is driven by TGF-β and IL-6, whereas 
IL-23 appears to expand or maintain eff  ector 
Th17 cell populations (19–23).
In addition to its eff  ects on T cell responses, 
IL-23 also has potent eff  ects on cells of the in-
nate immune system, inducing the production 
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of infl  ammatory cytokines, such as IL-1, IL-6, and TNF-α, 
by monocytes and macrophages (16, 24). The crucial role of 
innate immunity in intestinal infl  ammation was highlighted 
by the recent discovery that a substantial subgroup of human 
CD patients harbor mutations in the innate immune receptor 
NOD2, a cytoplasmic protein expressed by DCs, phagocytes, 
and some intestinal epithelial cells (25, 26). Although the 
mechanism by which NOD2 mutations predispose to the de-
velopment of CD has not yet been ascertained, the fi  nding 
that NOD2 recognizes a muropeptide motif derived from 
bacterial peptidoglycan (27) suggests that it may involve dys-
regulation of innate immune responses toward intestinal bac-
teria (28, 29). To study innate immune activation in intestinal 
pathology, we developed a model of T cell–independent 
  intestinal infl   ammation triggered by infection with the 
  pathogenic bacterium Helicobacter hepaticus. Infection of 
129SvEvRAG−/− mice with H. hepaticus led to the develop-
ment of chronic typhlocolitis mediated through activation 
and accumulation of innate immune cells, including granulo-
cytes and monocytic cells (30, 31). Innate immune typhlo-
colitis was inhibited by treatment with anti–IL-12p40 
monoclonal antibodies (30), indicating a requirement for 
IL-12 and/or IL-23 in disease. However, as bacteria-derived 
stimuli have been reported to induce secretion of both IL-12 
and IL-23 by DCs and monocytes (16, 32), their relative roles 
in intestinal pathology remain undefi  ned. Similarly, recent 
studies in CD patients (33, 34) reported elevated expression 
of both IL-12 and IL-23, highlighting this as a crucial issue 
for further study.
In this paper we have examined the role of IL-23 in two 
complimentary, well-characterized models of chronic intesti-
nal infl  ammation. In addition to the H. hepaticus–triggered 
innate immune model, we also used the T cell transfer model 
of colitis in which adoptive transfer of naive CD4+ T cells 
into C57BL/6 RAG−/− recipients leads to severe colitis that 
is associated with expansion and accumulation of activated 
T cells and DCs in the intestinal lamina propria (35, 36). Our 
results reveal a crucial role for IL-23, but not IL-12, in intes-
tinal infl  ammation mediated by sustained activation of either 
adaptive (CD4+ T cell–dependent) or innate immune mech-
anisms. The fi   nding that microfl   ora-induced IL-23 drives 
pathogenic innate and adaptive immune pathology locally in 
the intestine suggests that selective targeting of IL-23 may be 
an eff  ective therapeutic approach in human IBD.
RESULTS
IL-23 is essential for innate intestinal infl  ammation
We initially examined whether H. hepaticus–induced innate 
immune typhlocolitis was associated with excessive produc-
tion of IL-12 or IL-23 using real-time quantitative PCR 
(Q-PCR) to assay the expression of these cytokines in the 
normal and infl  amed intestine. As illustrated in Fig. 1 A, sig-
nifi   cantly increased expression of IL-23p19 and IL-12p40 
mRNA, but not of IL-12p35, was observed in the cecum 
and colon of H. hepaticus–infected (Hh+) 129SvEvRAG−/− 
mice. The increased expression of IL-23p19 was restricted to 
the intestine, as it was not observed in either the mesenteric 
LN (MLN) or spleen (Fig. 1 A).
As increased IL-17 expression has been associated with 
several IL-23–driven autoimmune T cell–mediated patholo-
gies (16), we analyzed whether increased IL-17 expression 
was also a feature of T cell–independent innate intestinal 
Figure 1.  Increased expression of IL-23 and IL-17 in infl  amed 
intestine. (A and B) RNA was purifi  ed from tissue samples isolated from 
H. hepaticus–infected (≥8 wk after infection) and control uninfected 
129SvEvRAG−/− mice, and cytokine gene expression was assayed using 
Q-PCR. For each individual sample, cytokine gene expression was normal-
ized relative to expression of HPRT (×104). Data shown represent mean 
relative expression levels (±SEM) from two independent experiments 
(n = 8–9 total mice per group). (C) Freshly isolated colon explants from 
H. hepaticus–infected and control uninfected 129SvEvRAG−/− mice were 
cultured overnight in complete RPMI, and cytokine release was measured 
using cytometric bead assay or ELISA. Results represent mean cytokine 
levels (±SEM; pg/100 mg colonic tissue) in samples pooled from three 
independent experiments (n = 9–12 total mice per group). (D and E) Spleen 
cells and LPLs (pooled from 6–12 mice) were isolated from H.  hepaticus–
infected 129SvEvRAG−/− mice and separated into the indicated subpopu-
lations using FACS sorting. IL-17 gene expression was assayed using 
Q-PCR and normalized relative to expression of HPRT (×104). Data 
shown represent mean relative expression levels (±SEM) from two 
 independent  experiments.JEM VOL. 203, October 30, 2006  2475
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  pathology. Somewhat unexpectedly, we observed a dramatic 
increase in expression of IL-17 in the infl  amed cecum of Hh+ 
129SvEvRAG−/− mice (Fig. 1 B), which was again restricted 
to the intestine, as it was not increased in spleen (Fig. 1 B). 
To confi  rm that these diff  erences in mRNA expression cor-
related with increased cytokine secretion, we cultured colon 
explants from Hh+ or control uninfected 129SvEvRAG−/− 
mice overnight and quantifi  ed cytokine release into the me-
dium. As shown in Fig. 1 C, signifi  cantly higher amounts of 
both IL-23 and IL-17 were produced by colon explants from 
Hh+ 129SvEvRAG−/− mice, but there was no increase in 
IL-12 secretion. To identify the innate sources of IL-17 in 
the intestine, we used cell sorting to isolate diff  erent popula-
tions of lamina propria leukocytes (LPLs) from Hh+ 
129SvEvRAG−/− mice. Three major subpopulations could 
be readily identifi  ed within the LPLs: Gr1+CD11b+ (pre-
dominantly granulocytes), Gr1−CD11b+ (monocytic cells), 
and Gr1−CD11b− cells (Fig. 1 D). Q-PCR analysis also 
  revealed that all leukocyte subpopulations isolated from the 
intestine expressed high levels of IL-17 mRNA (Fig. 1 E). In 
contrast, consistent with the results obtained using whole 
spleen samples (Fig. 1 B), leukocyte subpopulations isolated 
from the spleen of Hh+ 129SvEvRAG−/− mice expressed 
only very low levels of IL-17, around 100–1,000-fold lower 
than their intestinal counterparts (Fig. 1 E). Collectively, 
these results indicated that increased local production of IL-23 
and IL-17 correlated with innate intestinal pathology.
To formally assess the requirement for IL-23 in innate in-
testinal pathology, we used an anti–IL-23p19 monoclonal 
antibody to neutralize IL-23 in vivo. Although Hh+ 
129SvEvRAG−/− mice exhibited extensive infl  ammation in 
both the cecum and colon, treatment with anti-p19 through-
out the course of the experiment resulted in highly attenu-
ated intestinal pathology (Fig. 2 A). Anti-p19–treated mice 
had markedly reduced levels of infl  ammatory infi  ltrates and 
epithelial hyperplasia in the cecum and colon (Fig. 2 B). 
These results demonstrate that IL-23 plays an essential role in 
H. hepaticus–induced innate immune typhlocolitis.
IL-23 is essential for H. hepaticus–triggered systemic 
innate infl  ammatory responses
As Hh+ 129SvEvRAG−/− mice also exhibit marked systemic 
infl  ammatory responses (30), we next examined the eff  ect 
of anti–IL-23p19 treatment on these disease parameters. As 
shown in Fig. 3 (A and B), anti–IL-23p19 treatment signifi  -
cantly reduced H. hepaticus–induced splenomegaly in terms 
of both spleen weights and total spleen cell numbers. FACS 
analysis of spleen cells revealed that anti–IL-23p19 treat-
ment signifi  cantly reduced the accumulation of granulocytes 
and monocytes that was found in Hh+ 129SvEvRAG−/− 
mice (Fig. 3, C and D). Moreover, although scattered 
small infl  ammatory foci were present in the livers of Hh+ 
Figure 2.  IL-23 drives innate immune typhlocolitis. (A) 129SvEvRAG−/− 
mice were infected with H. hepaticus and treated i.p. with 1 mg/wk of 
anti–IL-23p19 or isotype control antibody throughout the course of the 
experiment. Mice were killed 6–8 wk later, and pathology in the cecum 
and colon was assessed histologically. Each symbol represents a single 
animal, and the data shown represent combined results from two inde-
pendent experiments (n = 4 total controls; and n = 8–9 total mice for 
experimental groups). Horizontal lines represent means. (B) Representa-
tive photomicrographs of tissue sections isolated from the mice outlined 
in A. Numbers indicate infl  ammation scores for the cecal sections shown. 
Bar, 500 μm.
Figure 3.  IL-23 drives systemic innate immune activation in 
H. hepaticus–infected 129SvEvRAG−/− mice. 129SvEvRAG−/− mice were 
infected with H. hepaticus and treated i.p. with 1 mg/wk of anti–IL-23p19 
or isotype control antibody throughout the course of the   experiment 
(6–8 wk). Spleen cell populations were enumerated using FACS analysis 
(reference 58). Graphs represent means ± SEM of (A) spleen weights, 
(B) spleen cell numbers, (C) granulocytes (FSCHiSSCHiGr1HiCD11bHiCD11c−), 
and (D) monocytes/macrophages (FSCHiSSCLoGr1IntCD11bHiCD11c−). 
Data shown represent combined results from two independent experiments 
(n = 4 total controls; and n = 8–9 total mice for experimental groups).2476  IL-23 DRIVES INTESTINAL PATHOLOGY | Hue et al.
129SvEvRAG−/− mice, these were not observed in mice 
that received anti–IL-23p19 (Fig. 2 B). These results demon-
strate that the systemic innate immune activation triggered by 
H. hepaticus infection is also dependent on IL-23.
Anti–IL-23p19 treatment decreases proinfl  ammatory 
cytokine production in the intestine
As the main producers of IL-23 are activated DCs and mac-
rophages(16), we reasoned that high levels of IL-23 pro-
duction might trigger a cascade of infl  ammatory cytokines 
that drives chronic intestinal infl  ammation. We therefore 
measured the levels of several proinfl  ammatory cytokines 
in intestinal tissue homogenates. Although colon homoge-
nates prepared from Hh+ 129SvEvRAG−/− mice contained 
markedly elevated levels of IL-6, monocyte chemoattrac-
tant protein–1 (MCP-1), IFN-γ, TNF-α, mouse chemo-
kine CXCL1 (KCs), and IL-1β, samples isolated from Hh+ 
129SvEvRAG−/− mice that had received anti–IL-23p19 
expressed similar low levels of proinfl  ammatory  cyto-
kines to uninfected controls (Fig. 4 A). Treatment of Hh+ 
129SvEvRAG−/− mice with anti–IL-23p19 also led to a 
similar reduction in IL-17 levels in the colon (Fig. 4 B), 
indicating that innate IL-17 production is also controlled by 
IL-23 in vivo. To confi  rm that anti–IL-23p19 was prevent-
ing intestinal pathology by inhibiting host innate immune 
activation and not through antibacterial eff   ects, we used 
Q-PCR to assess H. hepaticus infection levels. As shown in 
Fig. 4 C, treatment with anti–IL-23p19 had no eff  ect on 
the level of H. hepaticus colonization in 129SvEvRAG−/− 
mice. These results indicate that neutralization of IL-23 pre-
vents intestinal infl  ammation by inhibiting innate immune 
responses and suggest that high production of IL-23 in the 
intestine triggers a proinfl  ammatory cytokine cascade that 
mediates local and systemic pathology.
IL-23 is essential for T cell–mediated intestinal 
infl  ammation but not systemic infl  ammatory responses
To determine whether IL-23 was a general mediator of intes-
tinal infl  ammation, we next evaluated the roles of IL-12 and 
IL-23 in a well-established T cell–dependent model of IBD 
(35, 36). Thus, naive CD4+CD45RBhigh T cells isolated from 
C57BL/6 mice were adoptively transferred into age-matched 
cohorts of syngeneic RAG−/− recipient mice, p40−/−RAG−/− 
mice (lacking both IL-12 and IL-23), p35−/−RAG−/− mice 
(lacking only IL-12), or p19−/−RAG−/− mice (lacking only 
IL-23), and development of intestinal infl  ammation  was 
monitored. As illustrated in Fig. 5, the severe colitis induced 
by naive CD4+CD45RBhigh T cell transfer into RAG−/− re-
cipients was highly attenuated in p40−/−RAG−/− recipients, 
confi  rming that IL-12p40 was essential for disease. Strikingly, 
although p35−/−RAG−/− recipients developed colitis of sim-
ilar severity to that found in control RAG−/− recipients, in-
testinal infl  ammation was highly attenuated in p19−/−RAG−/− 
recipients (Fig. 5). These results clearly indicate that IL-23, 
but not IL-12, is required for the development of T cell–
  mediated colitis.
In addition to colitis, naive CD4+ T cell reconstitution of 
RAG−/− recipients also leads to systemic immune pathology, 
including splenomegaly and hepatic infl  ammation (35, 36). 
We therefore analyzed these parameters to examine the role of 
IL-23 in T cell–mediated systemic immune pathology. T cell–
mediated colitis was accompanied by marked splenomegaly 
in RAG−/− recipients and, even though this was signifi  cantly 
decreased in p40−/−RAG−/− recipients, there was no signifi  -
cant decrease in splenomegaly in either p35−/−RAG−/− or 
p19−/−RAG−/− recipients (Fig. 6, A and B). FACS analysis 
confi  rmed that the adoptively transferred CD4+ T cells had 
reconstituted the spleens of all groups of RAG−/− mice and, 
even though this was reduced in p40−/−RAG−/− recipients, 
there was no signifi   cant reduction in CD4+ T cells in 
p35−/−RAG−/− or p19−/−RAG−/− recipients (Fig. 6 C). A 
simi  lar pattern was observed with respect to liver pathology, 
with numerous prominent infl   ammatory foci present in 
RAG−/−, p35−/−RAG−/−, and p19−/−RAG−/− recipients but 
Figure 4.  IL-23 blockade reduces proinfl  ammatory cytokine pro-
duction in the intestine. 129SvEvRAG−/− mice were infected with 
H. hepaticus and treated i.p. with 1 mg/wk of anti–IL-23p19 or isotype 
control antibody throughout the course of the experiment (6–8 wk). 
(A and B) Cytokine concentrations in colon homogenates were measured 
and normalized to total protein content for each sample and are given as 
pg/mg total protein. Results represent mean cytokine levels (±SEM) from 
samples pooled from two similar experiments (n = 3–4 total samples per 
group). (C) Total amount of H. hepaticus DNA present in each cecal sample 
was determined using Q-PCR. Results represent mean H. hepaticus DNA 
levels (±SEM; n = 5 mice per group). H. hepaticus DNA was undetectable 
in cecal samples isolated from control uninfected mice.JEM VOL. 203, October 30, 2006  2477
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virtually absent in p40−/−RAG−/− recipients (Fig. 6 D). 
Collec  tively, these results show that IL-23 is not required for 
CD4+ T cell–mediated systemic infl  ammatory responses and 
further indicate that either IL-12 or IL-23 alone is able to 
  facilitate CD4+ T cell–dependent infl  ammatory responses in 
the liver and spleen.
T cell–dependent intestinal proinfl  ammatory cytokine 
production is attenuated in the absence of IL-23
As the T cell transfer colitis model has been associated with 
increased local Th1 responses (8), we also examined the lev-
els of several proinfl  ammatory cytokines in intestinal tissue 
homogenates from the various groups of RAG−/− recipi-
ents. Although colon homogenates isolated from control 
RAG−/− recipients contained elevated levels of TNF-α, 
IFN-γ, IL-6, MCP-1, IL-1β, and KC, these levels were 
markedly decreased in p40−/−RAG−/− recipients (Fig. 7). As 
expected, p35−/−RAG−/− recipients with colitis expressed 
similarly elevated levels of proinfl   ammatory cytokines as 
control RAG−/− recipients, whereas these were again at-
tenuated in p19−/−RAG−/− recipients (Fig. 7). These results 
demonstrate that IL-23, but not IL-12, is required for the 
effi   cient expression of proinfl  ammatory cytokine cascades in 
the intestine.
As IL-23 has been strongly associated with proinfl  amma-
tory IL-17–secreting CD4+ T cells (Th17), we also examined 
the levels of IL-17 in the colon homogenates and assayed for 
Th17 cells using intracellular FACS analysis. The highest lev-
els of IL-17 were detected in colon homogenates isolated 
from p35−/−RAG−/− recipients (Fig. 8 A). In contrast, only 
low levels of IL-17 were present in colon homogenates from 
p40−/−RAG−/− or p19−/−RAG−/− recipients (Fig. 8 A). 
CD4+ T cells isolated from the MLN and LPLs of RAG−/− 
or p35−/−RAG−/− recipients contained a high proportion of 
IFN-γ+ cells and a small population of IL-17+ cells (Fig. 8 B 
and not depicted). Interestingly, CD4+ T cells isolated from 
p40−/−RAG−/− or p19−/−RAG−/− recipients showed a 
marked decrease in the frequency of IFN-γ+ cells but still 
contained a small population of IL-17+ cells (Fig. 8 B). These 
results show that T cell–mediated colitis correlates with in-
creased frequencies of IFN-γ–secreting Th1 cells in intestinal 
lymphoid tissue and increased levels of IL-17 in the colon, 
suggesting that both Th1 and Th17 cells may contribute to 
pathogenesis. They further show that neither IL-12 nor IL-23 
is absolutely required for the diff  erentiation of Th17 cells 
from naive CD4+ T cells in vivo.
D  I  S  C  U  S  S  I  O  N 
Until recently, it had been widely accepted that the chronic 
intestinal infl  ammation found in human CD patients, as 
well as in many animal models of IBD, was caused by 
IL-12–driven excessive CD4+ Th1 responses. However, the 
results presented in this paper clearly demonstrate that IL-23, 
but not IL-12, plays an essential role in the induction of 
chronic intestinal infl  ammation. Although the requirement 
for IL-23 in T cell–dependent colitis is consistent with pre-
vious fi  ndings on its ability to promote pathological T cell 
  responses, the demonstration that it is also essential for typh-
locolitis in Hh+ 129RAG−/− mice highlights a novel role 
for IL-23 in innate immune pathology in vivo.
Attenuation of intestinal infl   ammation by blockade or 
genetic ablation of IL-23 was accompanied by decreased 
production of many proinfl  ammatory cytokines, including 
Figure 5.  IL-23 drives T cell–mediated colitis. Cohorts of wild-type 
or IL-12/23–defi  cient RAG−/− mice were reconstituted with 4 × 105 
CD4+CD45RBhigh T cells by i.p. injection. Mice were killed 6–8 wk later, and 
pathology in the colon was assessed histologically. Each symbol repre-
sents a single animal, and data shown represent combined results from 
two independent experiments (n = 7–11 total mice per group). Horizontal 
lines represent means.
Figure 6.  T cell–mediated systemic infl  ammation does not require 
IL-12 or IL-23. Cohorts of wild-type or IL-12/23–defi  cient RAG−/− mice 
were reconstituted with 4 × 105 CD4+CD45RBhigh T cells by i.p. injection 
and killed 6–8 wk later. (A–C) Splenomegaly was assessed by measuring 
spleen weights (A) and spleen cell number (B), and CD4+ T cell reconstitu-
tion (C) was assessed using FACS analysis. Data represent means ± SEM 
from two similar experiments (n = 7–11 total mice per group). (D) Repre-
sentative photomicrographs of liver sections isolated from the mice out-
lined earlier in this legend. Bar, 500 μm.2478  IL-23 DRIVES INTESTINAL PATHOLOGY | Hue et al.
TNF-α, IFN-γ, MCP-1, IL-6, IL-1β, and KC, several of
which have been implicated in the pathogenesis of IBD. As 
IL-23 is produced rapidly by DCs and macrophages after 
exposure to pathogen-derived molecules (16, 32), the most 
straightforward interpretation of our data is that IL-23, pro-
duced in response to intestinal bacteria, triggers a proinfl  am-
matory cytokine cascade that, if left unchecked, can lead to 
the development of chronic intestinal infl  ammation. As IL-23R 
is also expressed by DCs and macrophage populations, it has 
been proposed that IL-23 secretion can drive an autocrine 
feedback loop that amplifi  es local expression of cytokines like 
IL-1β and TNF-α (37), which in turn stimulate release of 
additional proinfl  ammatory mediators by stromal, epithelial, 
and endothelial cells.
Our experiments also highlight some novel aspects of the 
regulation of IL-17 expression in intestinal infl  ammation in 
vivo. To date, IL-23 has been proposed to trigger IL-17 pro-
duction through the induction/expansion of a novel subset 
of CD4+ Th17 cells, which have been associated with auto-
immune pathology (12, 13, 18, 38). However, our analysis of 
Hh+ 129RAG−/− mice showed that, concomitant with the 
increased IL-23 expression, there was a striking increase in 
both IL-17 mRNA expression and protein release in infl  amed 
intestine, indicating that IL-23 also induces the secretion of 
IL-17 by non–T cells in an infl  ammatory  environment. 
FACS sorting revealed that several subpopulations of LPLs 
expressed high levels of IL-17, including granulocytes and 
monocytes. However, the accumulation of granulocytes and 
monocytes in the spleens of Hh+ 129RAG−/− mice did not 
correlate with an increase in splenic IL-17 expression, sug-
gesting that additional local signals in the infl  amed intestine 
are required. A previous study noted that neutrophils may 
produce IL-17 in response to LPS, suggesting that bacteria 
may provide one such signal (39). Increased expression of 
IL-17 has been reported in the intestinal mucosa of IBD 
  patients, and histological analysis suggested that both T cells 
and monocytes may act as sources of IL-17 in the infl  amed 
gut (40). The IL-17R is widely expressed, and IL-17 binding 
promotes stromal, endothelial, and epithelial cells to secrete 
proinfl  ammatory mediators that recruit neutrophils to sites of 
infl  ammation (41). Together with our previous fi  nding that a 
prominent granulocytic infi  ltrate is characteristic of H. hepaticus–
induced innate typhlocolitis (30), this supports a role for 
IL-17 in the induction of innate intestinal pathology and sug-
gests that several cell types may contribute to IL-17 produc-
tion in the gut.
A very recent study reported that the T cell–mediated 
colitis that develops in IL-10−/− mice or in RAG−/− recipients 
Figure 7.  IL-23 defi  ciency results in decreased levels of proin-
fl  ammatory cytokine production in the intestine. Cohorts of wild-
type or IL-12/23–defi  cient RAG−/− mice were reconstituted with 4 × 105 
CD4+CD45RBhigh T cells by i.p. injection and killed 6–8 wk later. Cytokine 
concentrations in colon homogenates were measured and normalized 
to total protein content for each sample and are given as pg/mg total 
protein. Results represent mean cytokine levels (±SEM) from one of two 
similar experiments (n = 3–5 mice per group).
Figure 8.  IL-12 or IL-23 are not required for differentiation of 
IL-17–secreting CD4+ T cells in vivo. Cohorts of wild-type or IL-12/23–
defi  cient RAG−/− mice were reconstituted with 4 × 105 CD4+CD45RBhigh 
T cells by i.p. injection and killed 6–8 wk later. (A) IL-17 concentrations in 
colon homogenates were measured and normalized to total protein con-
tent for each sample and are given as pg/10 mg total protein. Results 
represent mean cytokine levels (±SEM) from one of two similar experi-
ments (n = 3–5 mice per group). (B) Pooled MLN cells were restimulated 
for 4 h with PMA and ionomycin in the presence of Brefeldin A. IFN-γ– and 
IL-17–secreting cells were detected using intracellular FACS analysis. 
  Results shown represent frequencies of cytokine-secreting cells among 
gated CD4+ cells and are representative of two similar experiments.JEM VOL. 203, October 30, 2006  2479
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of IL-10−/− CD4+ T cells was also dependent on IL-23 (42). 
Although this was associated with increased development of 
pathogenic Th17 cells, anti–IL-17 treatment had little impact 
on colitis and had to be combined with anti–IL-6 treatment 
to attenuate disease (42). These results indicate that even 
though IL-23–driven Th17 responses may play an important 
role in colitis, they constitute one of several potential innate 
and adaptive immune mechanisms that can contribute to in-
testinal pathology. Support for this hypothesis was obtained 
in a parallel study (see Kullberg et al. [43] on p. 2485 of this 
issue) that examined the role of IL-23 in two models of 
H. hepaticus–triggered T cell–dependent colitis. Though again 
highlighting a critical role for IL-23, these studies additionally 
identifi  ed a pathogenic role for IFN-γ, indicating that Th1 
and Th17 responses may synergize to elicit maximal pathol-
ogy during bacterially induced colitis (43). Similarly, in our 
T cell–mediated colitis model the correlation between IL-17 
and intestinal infl  ammation was not completely straightfor-
ward. Although elevated levels of IL-17 were found in colon 
homogenates from colitic RAG−/− and p35−/−RAG−/− re-
cipients, disease severity correlated with high frequencies of 
IFN-γ–secreting T cells, whereas only low proportions of 
IL-17–secreting T cells were present. These results again sug-
gest that both Th1 and Th17 cells contribute to IL-23–
  dependent colitis. In addition, our observations that small 
populations of IL-17–secreting T cells were present in both 
p40−/−RAG−/− and p19−/−RAG−/− recipients clearly indi-
cate that neither IL-12 nor IL-23 is required for diff  erentia-
tion of IL-17–secreting T cells in vivo. These fi  ndings are in 
accord with those of a very recent study in which infection 
with the intestinal bacterial pathogen Citrobacter rodentium 
elicited potent Th17 responses in both wild-type and p19−/− 
mice (21). However, despite mounting strong Th17 re-
sponses, p19−/− mice had less colonic infl  ammation  and 
failed to clear the C. rodentium infection, indicating that 
IL-23–driven infl  ammatory responses were an integral com-
ponent of the protective response (21).
Interestingly, a study using the dextran sulfate sodium 
model of acute colitis reported that neutralization of IL-17 
exacerbated intestinal infl  ammation, suggesting an inhibitory 
role for IL-17 in this disease (44). Furthermore, in vitro ex-
periments using intestinal epithelial cell monolayers suggested 
that IL-17 could enhance mucosal barrier function (45). Sev-
eral recent studies have clearly shown that TGF-β, in the 
presence of proinfl  ammatory cytokines such as IL-6, induces 
the diff  erentiation of Th17 cells (20–22). Conversely, in the 
absence of infl   ammatory mediators, TGF-β promotes the 
development of Foxp3+ T reg cells associated with suppres-
sion of infl  ammatory responses(21, 22, 46–49). These para-
doxical observations illustrate the complexity of immune 
regulation in the intestine and indicate that understanding 
how interactions between pleiotropic factors such as IL-17 
and TGF-β infl   uence intestinal homeostasis presents an 
  important future challenge.
As increasing scrutiny is given to the role of IL-23 in 
infl  ammatory responses, it is becoming apparent that it is 
a gross oversimplifi  cation to consider the IL-23–IL-17 and 
IL-12–IFN-γ pathways as two independent (and often mu-
tually exclusive) axes of immune pathology. Instead, we fa-
vor the idea that IL-23 is a central conductor of a range of 
innate and adaptive infl  ammatory responses and that IL-23 
itself may be regulated at several levels. Although bacterial 
stimuli may be a major inducer of IL-23 secretion, adap-
tive immune processes may also modulate its production. 
In support of this, we have recently observed that injection 
of agonistic anti-CD40 monoclonal antibody induces an 
IL-23–dependent acute infl  ammatory response in RAG−/− 
mice that was accompanied by intestinal infl  ammation (50). 
In contrast to most other models, anti-CD40–induced coli-
tis was independent of the presence of a bacterial microfl  ora 
(50), indicating that there is an alternative route of IL-23 
induction. The anti-CD40 treatment most likely mimicked 
strong T cell activation, characterized by marked up-regulation 
of CD40L that can then signal through CD40 on APCs. 
Thus, during sustained immune responses, activated T cells 
may provide a positive feedback loop for inducing further 
production of IL-23, thereby perpetuating infl  ammation. 
It would also seem important to have means of inhibiting 
IL-23 production and, because T reg cells and IL-10 have 
been implicated in down-modulation of innate and adap-
tive infl  ammatory responses, these seem obvious candidates. 
In fact, macrophages isolated from IL-10−/− mice show 
  elevated secretion of both IL-12 and IL-23 in response to 
bacterial stimuli (51).
Another important observation in these studies was that 
even though IL-23 was essential for local tissue infl  ammation 
in the intestine, it was not required for systemic infl  amma-
tory responses. This was clearly shown in the T cell transfer 
model of disease in which, even though colitis was highly 
attenuated in p19−/−RAG−/− mice, there was no inhibi-
tion of splenomegaly or in development of infl  ammatory 
foci in the liver. This suggests that IL-23 may be especially 
important for infl  ammatory responses within peripheral tis-
sues, which is consistent with previous experimental obser-
vations in models of autoimmune infl  ammation in the brain 
(11) and joints (13) and in infl  ammation induced by bacterial 
pathogens in the lung (52) and intestine (21). Together with 
our results, these studies are consistent with the hypothesis 
that the natural function of IL-23 in host defense may be 
in coordinating infl  ammatory responses against bacterial in-
fection in peripheral tissues, but that dysregulated expression 
of IL-23 may promote harmful immune pathology in these 
sites. This is consistent with the expression profi  le of IL-23 in 
Hh+ RAG−/− mice, where up-regulated IL-23 was present 
only in the cecum and colon but not in peripheral lymphoid 
tissues. Our fi  ndings that splenomegaly and liver infl  amma-
tion in Hh+ RAG−/− mice were also attenuated after treat-
ment with anti-p19 may refl  ect the sequential activation of 
local and systemic infl  ammatory responses in this model. 
In this case, we postulate that disease follows an “outside-
in” sequence by which infection with the bacteria triggers 
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cytokines and bacterial proinfl  ammatory molecules reaching 
the systemic circulation. These in turn feed the systemic cy-
tokine cascade that drives splenomegaly and liver pathology; 
therefore, preventing the initial infl  ammation in the intestine 
also shuts down the downstream systemic sequelae. In con-
trast, the T cell transfer model may represent an “inside-out” 
sequence in which naive T cell reconstitution is followed 
by a rapid T cell expansion in systemic lymphoid tissues. In 
the absence of T reg cells, this expansion proceeds in a dys-
regulated manner, allowing the excessive accumulation of 
both autoaggressive T cells that can mediate systemic infl  am-
matory responses as well as bacterially reactive T cells that 
mediate intestinal infl  ammation. In this case, although IL-23 
defi  ciency prevents the bacterially reactive T cells from caus-
ing colitis, it does not inhibit systemic T cell expansion and 
associated infl  ammation.
One additional point to note is that even though IL-23 is 
clearly a central mediator of intestinal infl  ammation, there 
may be additional IL-23–independent infl  ammatory  path-
ways that also contribute to disease. This hypothesis is sup-
ported by our fi  ndings that although highly attenuated, some 
mild infl   ammation persisted in the anti-p19–treated Hh+ 
129RAG−/− mice, mainly in the cecum, where the highest 
levels of H. hepaticus colonization occur (30). This indicates 
that pathogenic bacteria can also activate alternative innate 
immune mechanisms that synergize with IL-23 to drive se-
vere pathology. It is clear that excessive immune responses of 
almost any variety, Th1 cell, Th2 cell, or innate immunity, 
can mediate intestinal infl  ammation (1, 2).
The increasing clinical use of biological therapies such as 
infl  iximab (anti–TNF-α) in human IBD illustrates the poten-
tial benefi  ts that may be derived through molecular analysis 
of immune pathogenesis. However, the long-term eff  ects of 
such therapies are still unknown and, given the essential role 
of TNF-α in host defense, concerns have been voiced over 
possible increased incidences of infections, such as Mycobacteria, 
or tumors (53). Although some encouraging results have 
been obtained in initial clinical trials of anti–IL-12p40 in CD 
(9), the central role of IL-12 in resistance against many patho-
genic infections (54) suggests that long-term administration 
may similarly depress systemic immune function. Agents that 
target IL-23 may have the advantage of selectively decreasing 
local immune responses in affl   icted tissues while sparing sys-
temic immune protective mechanisms, a highly desirable 
property for effi   cient therapeutic agents for IBD.
MATERIALS AND METHODS
Mice. 129SvEvRAG2−/− mice and wild-type B6, control B6RAG1−/−, 
and IL-12/23–defi  cient strains on a B6RAG1−/− background (IL-12p40−/
−RAG−/−, IL-12p35−/−RAG−/−, and IL-23p19−/−RAG−/− mice) were 
bred and maintained under specifi  c pathogen-free conditions in accredited 
animal facilities at the University of Oxford. Experiments were conducted in 
accordance with the UK Scientifi  c Procedures Act of 1986. Mice were rou-
tinely screened for the presence of Helicobacter spp. and were >6 wk old 
when fi  rst used.
Bacteria. H. hepaticus NCI-Frederick isolate 1A (strain 51449; American 
Type Culture Collection) was grown on blood agar plates containing trime-
thoprim, vancomycin, and polymixin B (all obtained from Oxoid) under 
microaerophilic conditions as previously described (30, 55). For H. hepaticus 
infections, bacterial viability was confi  rmed using fl  uorescent microscopy 
with a bacterial live/dead kit (BacLight; Invitrogen), and 129SvEvRAG2−/− 
mice were fed three times on alternate days with  5 × 107–2 × 108 CFU 
H. hepaticus.
Antibody treatment. Anti–IL-23p19 monoclonal antibody (PAB1106) 
was produced and characterized as previously described (56). Antibody treat-
ment was commenced on the day of the fi  rst inoculation with H. hepaticus, 
and mice received weekly i.p. injections of 1 mg anti–IL-23p19 or isotype 
control for the duration of the experiment.
Induction of colitis with naive CD4+CD45RBhigh T cells. Naive 
CD4+CD45RBhigh T cells were isolated from spleens of C57BL/6 mice 
  using FACS sorting as previously described (57). In brief, single cell suspen-
sions were depleted of CD8+, MHC class II+, Mac-1+, and B220+ cells by 
negative selection using a panel of rat monoclonal antibodies, followed by 
sheep anti–rat–coated Dynabeads (Dynal). After staining with Cy-Chrome–
conjugated anti-CD4, PE-conjugated anti-CD25, and FITC–anti-CD45RB 
(all obtained from BD Biosciences), naive CD4+CD25−CD45RBhigh 
T cells were purifi  ed ( 99%) by cell sorting with a cell sorter (MoFlo; 
  DakoCytomation). Sex-matched control or IL-12/23–defi  cient B6RAG−/− 
mice received 4 × 105 CD4+CD45RBhigh T cells by i.p. injection, and 
  development of intestinal infl  ammation was monitored as described in the 
next paragraph.
Assessment of intestinal infl  ammation. Mice were killed when symp-
toms of clinical disease (weight loss or diarrhea) became apparent in control 
groups, usually 6–8 wk after initiation of experiments. Samples of liver, 
  cecum, and proximal, mid-, and distal colon were immediately fi  xed in buff  -
ered 10% formalin. 4–5 μm of paraffi   n-embedded sections was stained with 
hematoxylin and eosin, and infl  ammation was assessed as previously de-
scribed (30, 57). Each sample was graded semiquantitatively from 0 to 4, and 
typical features of each grade are as follows: 0 = normal; 1 = mild epithelial 
hyperplasia; 2 = pronounced hyperplasia with substantial infl  ammatory 
  infi  ltrates; 3 = severe hyperplasia and infi  ltration with marked decrease in 
goblet cells; and 4 = severe hyperplasia, severe transmural infl  ammation, 
  ulceration, crypt abscesses, and severe depletion of goblet cells. Ceca and 
  colons were assessed separately, and three separate sections from each sample 
were examined. The total colonic score was obtained by adding the individual 
scores from the sections of proximal, mid-, and distal colon.
Flow cytometry. Aliquots of 1–5 × 105 cells were stained in FACS buff  er 
(HBSS, 0.1% BSA, 5 mM EDTA; both obtained from Sigma-Aldrich) using 
the following panel of monoclonal antibody to mouse cell surface molecules 
(all obtained from BD Biosciences): biotinylated anti–NK cells (DX5), 
biotinylated anti-Gr1 (Ly6G), allophycocyanin-conjugated anti-CD11b, 
PE–anti-CD11c, PerCP-conjugated anti-CD4, and PE–anti–mouse TCRβ. 
Biotinylated antibodies were detected using PE-, allophycocyanin-, or 
FITC-conjugated streptavidin (all obtained from BD Biosciences). Samples 
were fi  rst incubated for 10 min with Fc block (eBioscience) to block any 
nonspecifi   c binding, and subsequent staining steps were performed for 
20 min on ice, followed by washing with FACS buff  er. Samples were fi  xed 
in FACS buff  er containing 2% paraformaldehyde (Biolab) acquired using a 
FACSCalibur (Becton Dickinson) and analyzed with software (FlowJo; Tree 
Star, Inc.). For intracellular cytokine analysis, cells were incubated in com-
plete RPMI 1640 (10% heat-inactivated FCS, 2 mM l-glutamine, 100 U/ml 
penicillin and streptomycin [obtained from Invitrogen], and 0.05 mM 
2-mercaptoethanol [obtained from Sigma-Aldrich]) containing 0.1 μM PMA 
and 1 μM ionomycin (both obtained from Sigma-Aldrich), plus 10 μg/ml 
Brefeldin A (Sigma-Aldrich), for 4 h at 37°C in a humidifi  ed incubator 
with 5% CO2. Cell surface staining was performed as described previously in 
this paper, and, after fi  xing, the samples were incubated in permeabiliza-
tion buff   er (PBS, 0.1% BSA, 0.5% saponin; Sigma-Aldrich) containing JEM VOL. 203, October 30, 2006  2481
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  allophycocyanin–anti–mouse IFN-γ, PE–anti–mouse IL-17 or appropriate 
isotype controls, allophycocyanin–rat IgG1, and PE–rat IgG2b (all obtained 
from BD Biosciences) for 30 min at room temperature, washed in permea-
bilization buff  er, and analyzed as described in this paper.
Isolation of leukocyte subpopulations. Spleen cells and LPLs were iso-
lated from 6–12 pooled Hh+129SvEvRAG2−/− mice as previously described 
(30). Cells were stained with fl  uorescent antibodies, and leukocyte subpopu-
lations were purifi  ed using FACS sorting as outlined previously in this paper. 
Cells were sorted into distinct subpopulations on the basis of size (forward 
scatter [FSC]) and granularity (side scatter [SSC]) in combination with 
  surface marker expression (58). Characteristics of subpopulations were as 
follows: granulocytes, FSCHiSSCHiGr1HiCD11bHiCD11c−; monocytes, 
FSCHiSSCLoGr1IntCD11bHiCD11c−; DCs, FSCHiSSCLoGr1−CD11cHi; and 
NK cells, FSCLoSSCLoDX-5Hi.
Quantitation of cytokine gene expression using real-time PCR. 
RNA was purifi   ed from frozen tissue samples or sorted cells using 
RNAeasy kits (QIAGEN). Homogenization was performed using a Poly-
tron Homogenizer (Kinematica AG). RNA purity and quantifi  cation 
was determined using a Nanodrop spectrophotometer (Nanodrop Tech-
nologies). cDNA synthesis was performed using a reverse transcrip-
tase kit (Superscript III) with Oligo dT (both obtained from Invitrogen). 
Q-PCR reactions were performed using the following primers, together 
with FAM/TAMRA- or VIC/TAMRA-labeled probes: HPRT primers, 
5′-G  A  C  C  G  G  T  C  C  C  G  T  C  A T  G  C  -3′ and 5′-T  C  A T A  A  C  C  T  G  G  T  T  C  A T  C 
A  T  C  G  C  -3′, and probe, 5′-A  C  C  C  G  C  A  G  T  C  C  C  A  G  C  G  T  C  G  T  C  -3′; IL-
23p19 primers, 5′-A  G  C  G  G  G  A  C  A  T  A  T  G  A  A  T  C  T  A  C  T  A  A  G  A  G  A  -3′ and 
5′-GTCCTAGTAGGGAGGTGTGAAGTTG-3′, and probe, 5′-CCAGT  T-
  CTGCTTGCAAAGGATCCGC-3′; IL-12p35 primers, 5′-T  A C  T A G  A G  A G  A C  -
T  T  C  T  T  C  C  A  C  A  A  C  A  A  G  A  G  -3′ and 5′-T  C  T  G  G  T  A  C  A  T  C  T  T  C  A  A  G  T  C  C-
  T  C  A T A G  A  -3′, and probe, 5′-A  G  A C  G  T  C  T  T  T  G  A T  G  A T  G  A C  C  C  T  G  T  G  C  C  T -3′; 
IL-12p40 primers, 5′-G  A  C  C  A T  C  A  C  T  G  T  C  A  A  A  G  A  G  T  T  T  C  T A  G  A T -3′ and 
5′-A  G  G    A  A  A  G  T  C  T  T  G  T  T  T  T  T  G  A  A  A  T  T  T  T  T  T  A  A  -3′, and probe, 5′-C  C-
A  C  T  C  A  C  A  T  C  T  G  C  T  G  C  T  C  C  A  C  A  A  G  A  A  G  -3′; and IL-17A primers, 
5′-G  C  T  C  C  A  G  A  A  G  G  C  C  C  T  C  A  G  -3′ and 5′-C  T  T  T  C  C  C  T  C  C  G  C  A  T  T  G-
A  C  A  -3′, and probe, 5′-A  C  C  T  C  A  A  C  C  G  T  T  C  C  A  C  G  T  C  A  C  C  C  T  G  -3′.
cDNA samples were assayed in triplicate using a detection system 
(Chromo4; GRI), and cytokine gene expression levels for each individual 
sample were normalized relative to HPRT using ∆Ct calculations (59).
Quantitation of cytokine protein levels in intestinal tissues. In initial 
experiments, small pieces of colon ( 5 mm of mid-colon) were isolated and 
rinsed in HBSS/BSA and weighed. Colon explants were cultured overnight 
in 24-well tissue culture plates (Costar) in 500 μl complete RPMI 1640 at 
37°C in an atmosphere containing 5% CO2. After centrifugation at 10,000 g 
to pellet debris, culture supernatants were transferred to fresh tubes and 
stored at –20°C. Cytokine concentrations were measured using specifi  c 
sandwich ELISAs (IL-23, R&D Systems; IL-17, Bio-Rad Laboratories) and 
were normalized to the weight of the colon explant.
For more comprehensive analysis, frozen intestinal tissue samples were 
homogenized in PBS containing a cocktail of protease inhibitors (Protease 
Inhibitor Cocktail Tablets; Roche) using a Polytron Homogenizer. After 
centrifugation at 10,000 g to pellet debris, concentrations of a panel of 
  proinfl  ammatory cytokines in supernatants were measured either using the 
cytometric bead assay (BD Biosciences) or the Luminex 100 assay (Bio-Rad 
Laboratories). In all cases, cytokine levels were normalized to the total 
  protein level in each sample, as measured using the Bradford assay (Bio-
Rad Laboratories).
Quantitation of H. hepaticus using real-time PCR. DNA was purifi  ed 
from cecal contents taken from H. hepaticus–infected mice using the DNA 
Stool kit (QIAGEN). H. hepaticus DNA was determined using a Q-PCR 
method based on the cdtB gene and performed with a Chromo4 detection 
system, as previously described (30, 60).
Statistics. The nonparametric Mann-Whitney test was used for comparing 
pathology scores and Q-PCR data, and an unpaired t test was used to exam-
ine spleen weights and cell counts. Diff  erences were considered statistically 
signifi  cant when P < 0.05.
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